Corporate Partners

Celgene Corp.

Collaboration and licensing agreement with Celgene Corp. to develop bispecific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric™ platform. Under the terms of the agreement, Zymeworks and Celgene are collaborating on the research and development on up to 10 bispecific antibodies with Celgene. Zymeworks received an initial up-front payment as well as a significant equity investment from Celgene. Zymeworks is eligible to receive clinical, regulatory, and commercial milestones on successful candidates totaling up to US $164M per therapeutic candidate. Additionally, Zymeworks will receive royalties on worldwide net sales.

 

Daiichi Sankyo

Zymeworks and Daiichi Sankyo began working together in September 2016 through an agreement to develop one bispecific antibody therapeutic for which Zymeworks is eligible to receive preclinical, clinical, and commercial milestones payments, as well as up to double-digit tiered royalties on global product sales. Additionally, Zymeworks obtained a license to certain immuno-oncology antibodies from Daiichi Sankyo, with the right to research, develop, and commercialize multiple bispecific products globally in exchange for royalties on global product sales.

In 2018, Daiichi Sankyo entered in a second agreement with Zymeworks and acquiredlicenses to Zymeworks’ Azymetric™ and EFECT™ technology platforms to develop two additional bispecific antibody therapeutics. In exchange, Zymeworks will receive an upfront technology access fee of US$18 million and may receive up to US$466.7 million in potential clinical, regulatory and commercial milestone payments. In addition, Zymeworks will receive up to double-digit tiered royalties on global product sales.

 

GlaxoSmithKline

Collaboration and license agreement with GlaxoSmithKline (GSK) for the research, development, and commercialization of novel Fc-engineered monoclonal and bispecific antibody therapeutics which have been optimized for specific therapeutic effects. Under the agreement, Zymeworks and GSK are collaborating to further develop Zymeworks’ Effector Function Enhancement and Control Technology (EFECT™) platform through the design, engineering, and testing of novel engineered Fc domains tailored to induce specific antibody-mediated immune responses. Both GSK and Zymeworks will have the right to develop and commercialize therapeutic antibody candidates incorporating Zymeworks’ optimized immune-modulating Fc domains. Zymeworks is eligible to receive pre-clinical, clinical, and commercial milestones of up to US $110 million per therapeutic candidate developed by GSK, as well as tiered sales royalties. 

License agreement with GSK for the research, development, and commercialization of novel bispecific antibodies enabled using Zymeworks' Azymetric™ platform. Under the agreement, GSK will have the option to develop and commercialize multiple bispecific drugs across different disease areas. Zymeworks will receive upfront and preclinical payments of up to USD$36 million and is eligible to receive up to USD$152 million in development and clinical milestone payments, along with commercial sales milestone payments of up to USD$720 million, and tiered royalties on potential sales. As part of this second agreement, GSK has gained the right to combined the Azymetric™ platform with novel engineered Fc domains developed under the previously announced collaboration.

 

Johnson & Johnson Innovation & Janssen Biotech, Inc.

Collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the research,development, and commercialization of next generation bispecific antibody therapeutics enabled using Zymeworks' Azymetric™ and EFECT™ platforms. Under the terms of the agreement, Zymeworks will provide Janssen with a worldwide, royalty-bearing license to research, develop, and commercialize up to six bispecific antibodies directed to Janssen therapeutic targets using Zymeworks’ Azymetric™ and EFECT™ platforms. Janssen will be responsible for all research, development, and commercial activities under the licensing agreement. Zymeworks will receive an upfront payment of US$50 million and is eligible to potentially receive up to US$282 million in development and up to US$1.12 billion in commercial milestone payments, and tiered royalties on potential sales. Janssen also has the option to develop two additional bispecific programs under the agreement subject to a future option payment. 

 

Eli Lilly & Co.

Collaboration with Eli Lilly and Company to develop bispecific antibodies, using Zymeworks’ proprietary Azymetric™ platform, against multiple Lilly targets for immunotherapy and other applications. Under the terms of the agreement, Zymeworks has granted Lilly a worldwide license to the Azymetric™ platform to develop and commercialize therapeutic candidates in exchange for up to US $375 million in milestones and other payments, plus tiered sales royalties. In addition, Zymeworks received an initial up-front payment in the form of an equity investment.

 

Merck & Co.

Collaboration with Merck to develop bispecific antibody therapeutics using Zymeworks’ Azymetric™ platform. Under the terms of the original agreement (2011) and the expanded collaboration (2014), Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bispecific antibodies generated through use of the Azymetric™ platform toward certain therapeutic targets. Both companies will collaborate to advance the technology platform and to progress bispecific therapeutic antibody candidates in pre-clinical development with Merck responsible for clinical development and commercialization.